SCHEMBL6493992

SCHEMBL6493992

Cc1cnc(C(CC(=O)O)Cc2ccc(O)cc2)s1

nearest known ligand 0.46

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CTSA P10619 19/20 0.46
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7804223 0.86 CTSA (0.42) CTSA
SCHEMBL6499973 0.85 PKM (0.51) CTSAPKM
SCHEMBL6176693 0.76 PKM (0.44) PKM
SCHEMBL6175673 0.76 CTSA (0.45) CTSAPKM
SCHEMBL6179589 0.76 CTSA (0.45) CTSAPKM
SCHEMBL6177067 0.76 CTSA (0.45) CTSAPKM
SCHEMBL27510388 0.75 MAOB (0.53) CTSAPKM
SCHEMBL6490652 0.73 ITGB3 (0.73)
SCHEMBL6177984 0.72 PKM (0.75) PKM
SCHEMBL16109287 0.71 CTSA (0.58) CTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020123489-A1 Benzamidine derivatives ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-09-05 US claimed
WO-2002048122-A2 BENZAMIDINE DERIVATIVES ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-06-20 WO claimed
US-6881736-B1 Vitronectin receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 2005-04-19 US disclosed
EP-1218005-B1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-12-15 EP disclosed
EP-1218005-A4 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-10-09 EP disclosed
EP-1218005-A2 VITRONECTIN RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-07-03 EP disclosed
WO-2001017959-A2 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123489-A1 Benzamidine derivatives OPRD1, OPRK1, OPRM1 CTSA 1620/4885PKM 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.